Evotec SE (NASDAQ:EVO) Sees Significant Drop in Short Interest

Evotec SE (NASDAQ:EVO - Get Free Report) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 660,800 shares, a decrease of 18.0% from the March 31st total of 806,300 shares. Approximately 0.2% of the company's shares are short sold. Based on an average trading volume of 83,600 shares, the short-interest ratio is presently 7.9 days.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft raised shares of Evotec from a "sell" rating to a "hold" rating in a research report on Thursday, April 24th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in Evotec in the 4th quarter worth $27,000. Bank of America Corp DE lifted its stake in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares in the last quarter. CSS LLC IL acquired a new stake in Evotec during the 4th quarter valued at approximately $50,000. DCF Advisers LLC grew its stake in Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after purchasing an additional 12,816 shares in the last quarter. Finally, Lighthouse Investment Partners LLC purchased a new stake in Evotec during the 4th quarter worth approximately $166,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.

Evotec Price Performance

NASDAQ EVO traded down $0.12 on Monday, reaching $4.17. The company had a trading volume of 23,799 shares, compared to its average volume of 127,477. The firm has a 50-day moving average of $3.62 and a 200-day moving average of $4.15. Evotec has a 1 year low of $2.84 and a 1 year high of $5.68. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.